Irinotecan
Papillary Renal Cell Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 89/ 100
Competitive context
21 Active assets in the Papillary Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide First Affiliated Hospital, Sun Yat-Sen University | Phase 3 | BB |
Pembrolizumab First Affiliated Hospital, Sun Yat-Sen University | Phase 3 | BB |
Cabozantinib National Cancer Institute (NCI) | Phase 2 | BB |
Volitinib AstraZeneca | Phase 3 | BB |
Durvalumab AstraZeneca | Phase 3 | B |
View all 35 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →